Xtant Medical (XTNT) investor relations material

Market opportunity and business transformation

• Significant market addressed in orthobiologics and expansion into new regenerative biologics segments.

• Achieved full vertical integration, now manufacturing all products in-house, improving supply security and margins.

• Divested Coflex and Paradigm OUS businesses, focusing on core strengths and streamlining operations.

• Over 450 IDN agreements and 500+ independent agents, demonstrating strong commercial reach.

• Domestic market opportunity estimated at $11.5 billion, with $3 billion addressable in orthobiologics.

Financial performance and balance sheet

• Year-over-year growth exceeded 19%, with organic CAGR of about 14% since 2021.

• Sale of Coflex and Paradigm OUS businesses brought in over $21 million, boosting cash reserves to $25 million and halving long-term debt to $11 million.

• Achieved profitability and positive cash flow, emphasizing self-sustainability.

• Improved financial profile expected to be reflected in upcoming Q4 and full-year results.

Product innovation and portfolio expansion

• Expanded from two to all five major orthobiologic segments, including allograft, demineralized bone, cellular allograft, growth matrix, and synthetics.

• Launched new product categories: amnion, growth factor, and stem cell lines, plus upgrades to demineralized bone products.

• Introduced high-ASP products like enhanced DBM and Trivium, with pricing over $250/cc, driving margin growth.

• Upcoming launches include E-Matrix collagen-based bone graft and Collagen X Pro.